 Fulgent Genetics Inc NASDAQ: FLGT reported Q3 sales of 227.9 million, 124 YY, beating the consensus of 264 million primarily driven by sales of its COVID-19 tests. Fulgent said that the billable tests delivered in the quarter grew to approximately 2.2 million, up from 1.04 million in Q3 2020. 